Results 131 to 140 of about 96,256 (296)

Host Cell Protein Challenges in Antibody Processing: Insights Into Persistence and Mitigation Strategies

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Persistence of HCPs remains a major purification challenge in biopharmaceutical manufacturing with direct consequences for product quality, patient safety, and regulatory compliance. Over the last two decades, deeper insights into the mechanisms driving HCP persistence have clarified why certain proteins evade removal during purification ...
Younghoon Oh, Andrew Cooke, Harshal Soni, Susan Liu, Mamadou Bah, Brianna Bellis, Laura Smith, Michael Capaldi, Nicholas Levy, Erik Wilhelm, Kristopher Barnthouse   +10 more
wiley   +1 more source

Transcriptomics-guided optimization of vitamins to enhance erythromycin yield in saccharopolyspora erythraea

Bioresources and Bioprocessing
Comparative transcriptomics uncovered distinct expression patterns of genes associated with cofactor and vitamin metabolism in the high-yielding mutant strain Saccharopolyspora erythraea HL3168 E3, as compared to the wild-type NRRL 2338.
Xiang Ke, Xing Jiang, Shuohan Wang, Xiwei Tian, Ju Chu   +4 more
doaj   +1 more source

Model‐Driven Monitoring and Parameter‐Based Development of an Escherichia coli Fed‐Batch Process for Production of a Fab Antibody Fragment Across Scales

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Maintaining consistent cellular physiology during bioprocess scale‐up or scale‐down is key to developing robust processes. However, the reliability of scale‐down bioreactor systems remains debated. Although the calibration of physiological parameters in mechanistic models across scales has been proposed as a scale‐down strategy, few studies ...
Fabian Schröder‐Kleeberg, Lucas Kaspersetz, Markus Zoellkau, Markus Glaser, Markus Brunner, Christian Bosch, Annina Kemmer, M. Nicolas Cruz Bournazou, Peter Neubauer   +8 more
wiley   +1 more source

Impact of chemical shock loads on a membrane bioreactor for urban wastewater reuse

, 2010
The performance of an MBR under chemical shock loading conditions was investigated, to ascertain the robustness of the treatment system for urban water reuse. 32 household products and industrial substances, likely to be found in urban wastewater were
Knops, Geraldine Jane Augustine
core   +1 more source

Low‐Field MRI as a Multiparametric Tool for Large Engineered Tissue Characterization

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Advances in 3D bioprinting have enabled the fabrication of large and complex engineered tissues, but their increasing size demands non‐invasive tools for monitoring structure, maturation, and perfusion. Magnetic Resonance Imaging (MRI) offers unique multiparametric capabilities, yet high‐field systems remain costly and inaccessible for most ...
Yilbert Gimenez, Valernst Martial Gilmus, Elliott Cowles, Lucie Essayan, Vincent Semet, Michel Cabrera, Christophe A. Marquette, Simon A. Lambert, Emma Petiot   +8 more
wiley   +1 more source

Scalable Separation and Purification of M13‐Bacteriophage‐Derived Particles Containing Artificial Single‐Stranded DNA Produced by Escherichia coli

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Single‐stranded DNA (ssDNA) solutions are promising innovations shaping the future of genetic research and medical therapies. In principle, biotechnological mass production of ssDNA can be achieved using Escherichia coli in a high‐cell density fed‐batch process by secreting phagemid particles derived from the filamentous M13 bacteriophages ...
Nathalie Hafner, Wiebke Winkler, Maximilian N. Honemann, Hendrik Dietz, Dirk Weuster‐Botz   +4 more
wiley   +1 more source

A General Workflow for Tangential Flow Filtration Perfusion Scale‐Up

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Tangential flow filtration (TFF) perfusion using hollow‐fiber modules offers substantial advantages over other mammalian cell retention technologies. Recently, increased awareness of Starling flow has helped to enhance filtration performance to similar, or even higher levels compared to alternative technologies.
Patrick Romann, Ken Lee, Venkatesh Natarajan, Daniel Ley, Claes Nymand Nilsson, David Garcia‐Munzer, Dominik Schieman, Mahbod Hajighasemi, Alex Zaytsev, Jason Friedman, Loic Chappuis, Tobias Habicher, Colin Jaques, Alex Cohen, Matthew Gagnon, Edward Chan, Daniel J. Karst, Philip Giller, Antony Sibilia, Andrew L. Zydney, Thomas K. Villiger   +20 more
wiley   +1 more source

Whole‐Cell Production of Resolvin E2 and 17R‐Resolvin D5 by a Double‐Oxygenating 15S‐Lipoxygenase With 5S‐Lipoxygenase Activity From Pseudobdellovibrionaceae bacterium

Biotechnology and Bioengineering, EarlyView.
A recombinant whole‐cell platform expressing a bacterial 15S‐LOX exhibiting 5S‐LOX activity enabled the stereoselective production of RvE2 and 17R‐RvD5 from 18R‐HEPE and 17R‐HDHA, achieving final concentrations of 0.57 mM and 1.48 mM from 4.0 mM substrates, respectively, under optimized conditions.
Hee‐Gyeong Lee, Kyung‐Chul Shin, Deok‐Kun Oh   +2 more
wiley   +1 more source

Isolating T‐Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion‐Exchange Adsorbents

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Generation of CAR‐T cell therapies relies predominantly on lentiviral vectors (LVs). As in vivo CAR‐T trials progress, demand for larger quantities of higher‐potency LV is expected. However, primary capture by anion‐exchange chromatography (AIEX) remains a major manufacturing bottleneck from use of adsorbents not tailored to LVs, leading to ...
George Pamenter, Gyorgy Ovari, Anurag Kulkarni, Thomas Williams‐Fegredo, Carol Knevelman, Kyriacos Mitrophanous, Lee Davies, Farzad Foroutan, Matthew Townsend, Stephen Goldrick, Daniel G. Bracewell   +10 more
wiley   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source